Scinovex
article Open AccessTop 10% cited

Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease

Gut · 2000 · Vol. 47(3) · pp. 397–403
Jean‐Pierre SegainD Raingeard de la BlétièreA BourreilleV LerayN GervoisC RosalesL FerrierC BonnetH M BlottièreJ-P Galmiche

Abstract

Butyrate decreases proinflammatory cytokine expression via inhibition of NFkappaB activation and IkappaBalpha degradation. These anti-inflammatory properties provide a rationale for assessing butyrate in the treatment of CD.

Inflammatory Bowel DiseaseNF-κB Signaling PathwaysImmune Response and InflammationProinflammatory cytokineButyrateTumor necrosis factor alphaCytokineLamina propriaLipopolysaccharideInflammationImmunologyPeripheral blood mononuclear cellBiology

MeSH terms

AdolescentAdultAgedAnimalsButyratesCells, CulturedCrohn DiseaseDose-Response Relationship, DrugDrug EvaluationFemaleGastrointestinal AgentsHumansInterleukin-1Leukocytes, MononuclearMale
Citations
1,308
FWCI
9.57
field-weighted impact
References
48
Percentile
98%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.